Kancera AB
🇸🇪Sweden
- Country
- 🇸🇪Sweden
- Ownership
- Public
- Established
- 2010-01-01
- Employees
- 3
- Market Cap
- -
- Website
- http://www.kancera.com
A Study to Evaluate the Safety of KAND567, in Combination with Carboplatin Therapy, in Women with Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase 1
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-10-17
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Kancera AB
- Target Recruit Count
- 18
- Registration Number
- NCT06087289
- Locations
- 🇩🇰
Odense University Hospital, Odense, Denmark
🇳🇴Oslo University Hospital, Oslo, Norway
🇸🇪Skåne University Hospital, Lund, Sweden
Evaluation of Safety, Tolerability, Pharmacokinetics, Food Effect and Interaction With Midazolam in Healthy Volunteers After Oral Single and Multiple Ascending Dosing of KAND145
- First Posted Date
- 2023-10-02
- Last Posted Date
- 2024-04-22
- Lead Sponsor
- Kancera AB
- Target Recruit Count
- 50
- Registration Number
- NCT06063343
- Locations
- 🇫🇮
Clinical Research Services Turku - CRST Oy, Turku, Finland
Safety, Tolerability and Pharmacokinetics After Continuous Infusion of KAND567
- First Posted Date
- 2023-09-11
- Last Posted Date
- 2023-09-11
- Lead Sponsor
- Kancera AB
- Target Recruit Count
- 23
- Registration Number
- NCT06030375
- Locations
- 🇫🇮
Clinical Research Services Turku (CRST), Turku, Finland
KAND567 Versus Placebo in Subjects Hospitalized With COVID-19
- First Posted Date
- 2023-08-25
- Last Posted Date
- 2023-08-25
- Lead Sponsor
- Kancera AB
- Target Recruit Count
- 35
- Registration Number
- NCT06012565
- Locations
- 🇩🇰
Odense University Hospital, Odense, Denmark
🇩🇰Hvidovre Hospital, Hvidovre, Denmark
🇸🇪Västmanlands Hospital, Västerås, Sweden
© Copyright 2024. All Rights Reserved by MedPath